Individualized therapy concepts are essential

After Alzheimer’s disease, Parkinson’s disease is currently the second most common neurodegenerative disease. The majority of those affected are ≥60 years old when it first manifests, but a minority develop the disease at a younger age. With suitable symptomatic therapies, the disease can often be well controlled for years. Consideration of the individual symptom profile is crucial here. A causal therapy does not yet exist, but disease-modifying approaches are being researched.